Anta Gkelou joined the Life Sciences team as an analyst in 2017. She conducted her post-doctoral training at the French National Institute of Health and Medical Research (INSERM) on immune regulation of the contractile machinery and cardiac function post myocardial infarction. She obtained her PhD in Clinical Medical Research from Imperial College London in collaboration with Pfizer where she worked on elucidating signaling pathways that regulate corticosteroid insensitivity in patients with Chronic Obstructive Pulmonary Disease (COPD). Anta holds a 1st class BSc in Molecular Biology from University of Liverpool, UK. Prior to joining Sofinnova, she was an Immunology Scientist in the Life Science Division of Danone Nutricia Research. Her research and review articles have been published in journals such as the Journal of Experimental Medicine, Current Opinion in Pharmacology, Journal of Inflammation and Hypertension.